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Progressive external ophthalmoplegia is a common clinical feature in mitochondrial disease caused by nuclear DNA defects and
single, large-scale mitochondrial DNA deletions and is less frequently associated with point mutations of mitochondrial DNA.
Peripheral neuropathy is also a frequent manifestation of mitochondrial disease, although its prevalence and characteristics
varies considerably among the different syndromes and genetic aetiologies. Based on clinical observations, we systematically
investigated whether the presence of peripheral neuropathy could predict the underlying genetic defect in patients with pro-
gressive external ophthalmoplegia. We analysed detailed demographic, clinical and neurophysiological data from 116 patients
with genetically-defined mitochondrial disease and progressive external ophthalmoplegia. Seventy-eight patients (67%) had a
single mitochondrial DNA deletion, 12 (10%) had a point mutation of mitochondrial DNA and 26 (22%) had mutations in either
POLG, C10orf2 or RRM2B, or had multiple mitochondrial DNA deletions in muscle without an identified nuclear gene defect.
Seventy-seven patients had neurophysiological studies; of these, 16 patients (21%) had a large-fibre peripheral neuropathy. The
prevalence of peripheral neuropathy was significantly lower in patients with a single mitochondrial DNA deletion (2%) as
compared to those with a point mutation of mitochondrial DNA or with a nuclear DNA defect (44% and 52%, respectively;
P50.001). Univariate analyses revealed significant differences in the distribution of other clinical features between genotypes,
including age at disease onset, gender, family history, progressive external ophthalmoplegia at clinical presentation, hearing
loss, pigmentary retinopathy and extrapyramidal features. However, binomial logistic regression analysis identified peripheral
neuropathy as the only independent predictor associated with a nuclear DNA defect (P = 0.002; odds ratio 8.43, 95% confidence
interval 2.24–31.76). Multinomial logistic regression analysis identified peripheral neuropathy, family history and hearing loss
as significant predictors of the genotype, and the same three variables showed the highest performance in genotype classifi-
cation in a decision tree analysis. Of these variables, peripheral neuropathy had the highest specificity (91%), negative pre-
dictive value (83%) and positive likelihood ratio (5.87) for the diagnosis of a nuclear DNA defect. These results indicate that
peripheral neuropathy is a rare finding in patients with single mitochondrial DNA deletions but that it is highly predictive of an
underlying nuclear DNA defect. This observation may facilitate the development of diagnostic algorithms. We suggest that
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nuclear gene testing may enable a more rapid diagnosis and avoid muscle biopsy in patients with progressive external oph-
thalmoplegia and peripheral neuropathy.
Keywords: mitochondrial DNA; mitochondrial DNA deletion; peripheral neuropathy; POLG; progressive external ophthalmoplegia
Abbreviations: MELAS = mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes; PEO = progressive external
ophthalmoplegia; PEO/CN = PEO with CNS involvement; SANDO = sensory ataxia, neuropathy, dysarthria and ophthalmoplegia
Introduction
Progressive external ophthalmoplegia (PEO) is a common presen-
tation and frequently the defining clinical feature of mitochondrial
respiratory-chain disease. It is characterized by slowly progressive,
painless, bilateral ptosis and generalized reduction of ocular move-
ments in all directions of gaze that is not usually associated with
diplopia or significant fluctuations (Lee and Brazis, 2002). Patients
may develop additional muscular, neurological or systemic fea-
tures, leading to a variety of syndromes that range from isolated
chronic PEO to those with multisystem involvement such as
Kearns-Sayre syndrome or mitochondrial neurogastrointestinal
encephalomyopathy (Chinnery and Shoubridge, 2010). These
must be distinguished from other non-mitochondrial disorders
causing ptosis and ophthalmoplegia such as myasthenia gravis,
oculopharyngeal muscular dystrophy, oculopharyngodistal myop-
athy or MYH2-related myopathy.
From a genetic perspective, PEO is associated with both primary
and secondary mitochondrial DNA defects (Hirano and DiMauro,
2001). The former include single, large-scale mitochondrial DNA
deletions, which are usually sporadic in occurrence and have a low
transmission risk, and maternally-inherited mutations in mitochon-
drial tRNA or protein-coding genes (e.g. MT-TL1, MT-TI and MT-
ND4) (Sweeney et al., 1993; Raffelsberger et al., 2001; Pulkes
et al., 2003; Smits et al., 2007; Nesbitt et al., 2013). The
second group include inherited defects in nuclear-encoded genes
involved in mitochondrial DNA replication and maintenance (e.g.
POLG, POLG2, C10orf2, SLC25A4, OPA1, SPG7, TYMP, RRM2B,
TK2 and DGUOK) that cause multiple deletions and/or depletion
of mitochondrial DNA (Agostino et al., 2003; Hudson et al., 2006,
2008; Fratter et al., 2011; Garone et al., 2011; Park et al., 2011;
Young et al., 2011; Ronchi et al., 2012; Tyynismaa et al., 2012;
Pfeffer et al., 2014). PEO is indeed a clinical hallmark of patients
with single mitochondrial DNA deletions but also the most
common presenting feature in adults with nuclear DNA defects.
Point mutations of mitochondrial DNA account for a smaller pro-
portion of cases. For instance, PEO has been reported to occur in
12% of patients with the most frequent point mutation, the
m.3243A4G transition in MT-TL1 [tRNALeu(UUA/G)] (Nesbitt
et al., 2013).
Peripheral neuropathy is also a well-recognized manifestation of
mitochondrial disease, although its prevalence and characteristics
vary considerably among the different syndromes and genetic
causes. It is a major or a common feature of a variety of nuclear
DNA defects (e.g. TYMP-, MPV17- and POLG-related disorders)
but also of certain point mutations of mitochondrial DNA (e.g.
m.8993T4G/C and m.3243A4G) (Holt et al., 1990; Karadimas
et al., 2006; Kaufmann et al., 2006; Garone et al., 2011; Lax
et al., 2012). However, there are only anecdotal reports of per-
ipheral neuropathy in patients with single mitochondrial DNA
deletions (Eymard et al., 1991; Reichmann et al., 1991; Molnar
et al., 1996). This observation suggests that peripheral nerve in-
volvement is extremely rare in this group of patients and contrasts
with the widespread tissue distribution of deleted mitochondrial
DNA species in some of them (e.g. Kearns-Sayre syndrome)
(Moraes et al., 1989; Ponzetto et al., 1990; Brockington et al.,
1995).
Mitochondrial respiratory-chain diseases often present with a
diverse constellation of clinical manifestations that may hinder
the distinction between phenotypes. Certain combinations of
symptoms, however, can suggest the specific aetiology. Based
on initial clinical and genetic observations, we hypothesized that
the presence of peripheral neuropathy might predict a nuclear
DNA defect in patients with PEO.
The main objectives of the present study were to determine the
frequency of peripheral neuropathy in a large cohort of patients
with genetically-defined mitochondrial disease and PEO and to
evaluate whether the presence of peripheral neuropathy or other
clinical features could predict the underlying genetic defect in the
same population. Secondary objectives were to define the propor-
tion of genotypes among patients with PEO and to describe the
characteristics of the peripheral neuropathy.
Materials and methods
Study design and patient selection
This was a retrospective, observational, single-centre study based on
chart review of patients fulfilling the following inclusion criteria: diag-
nosis of PEO (progressive ptosis and restriction of extraocular motility
in all directions of gaze) as judged by the examining neurologist; and
confirmed genetic defect of either mitochondrial DNA or nuclear-
encoded genes involved in mitochondrial DNA translation, replication
or maintenance. Cases were identified from a database of all patients
with mitochondrial disease and unaffected relatives assessed at the
MRC Centre for Neuromuscular Diseases, National Hospital for
Neurology and Neurosurgery, London, between 1985 and 2013
(Fig. 1). From a total of 145 candidates, medical records were available
for review for 120 probands. Four patients were excluded due to in-
sufficient clinical information. Demographic, clinical and paraclinical
data from the resulting 116 patients were abstracted into a standar-
dized form.
This study was performed under the ethical guidelines issued by our
institution for clinical audit studies. Written informed consent was ob-
tained from all subjects before genetic testing.
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Data collection
The following features were systematically collected: gender; date of
birth; family history of relatives with similar symptoms or phenotype;
ptosis; ophthalmoparesis; pigmentary retinopathy on fundoscopic
examination; hearing loss, symptomatic or confirmed on audiogram;
dysarthria; dysphagia; exercise intolerance; limb muscle weakness;
large-fibre peripheral neuropathy; pyramidal signs; ataxia, cerebellar
or sensory; seizures or epilepsy; stroke, stroke-like episodes or territor-
ial infarct on neuroimaging; movement disorders, including myoclonus,
dystonia and parkinsonism; diabetes; cardiac disorders; and date of last
follow-up or death. Other clinical characteristics were also recorded if
considered relevant. Complete medical assessments were assumed and
a feature was considered as absent when the history or examination
was explicitly reported as being unremarkable or normal except for
cardiac disorders, which were considered missing if not reported.
Emphasis was placed on reviewing and collecting symptoms potentially
related to peripheral neuropathy and findings from the motor and
sensory examination. Although subject to recall bias, an approximate
date (year) of symptoms onset and the presenting feature were also
recorded. Muscle biopsy findings and laboratory tests, including creat-
ine kinase, lactate, lactate/pyruvate ratio, renal and thyroid function
tests, glucose, HbA1c (glycated haemoglobin), folate and vitamin B12
levels, were collected where available.
Neurophysiology reports were available for review in 90 cases. In 13
of them, nerve conduction studies had been performed only in the
upper limbs. Of the remaining 77 patients, 43 had at least one sensory
and motor nerve studied in one upper and one lower limb; 24 had less
than one sensory and motor nerve studied in one upper and one lower
limb; and 10 had nerve conduction studies performed only in the
lower limbs. Of these 77 patients, 74 had nerve conduction studies
with or without EMG done using standard methods at the National
Hospital for Neurology and Neurosurgery, UK. In three cases, neuro-
physiological studies were performed at other tertiary hospitals. Two
authors (A.H. and J.C.B.) reviewed the reports for technical and inter-
pretation accuracy. Results were compared to normative data on
healthy individuals.
Molecular genetic analysis of mitochondrial DNA extracted from
blood, muscle or urine had been performed at the Neurogenetics
Unit, National Hospital for Neurology and Neurosurgery, London.
The presence of point mutations of mitochondrial DNA was confirmed
by PCR-restriction fragment length polymorphism (m.3243A4G), se-
quence analysis of MT-TL1 (m.3260A4G) (Sweeney et al., 1993), or
sequence analysis of the entire mitochondrial DNA and mismatch PCR
(m.12294G4A and m.11232T4C) (Pulkes et al., 2003). Large-scale
mitochondrial DNA rearrangements were confirmed by long-range
PCR and Southern blotting. Molecular analysis of nuclear genes ex-
tracted from blood or muscle had been performed by direct sequen-
cing at the Oxford Medical Genetics Laboratories.
Patient classification
For descriptive purposes, patients were classified into four phenotype
groups: chronic PEO with or without bulbar symptoms (dysarthria or
dysphagia), limb weakness or other features but no CNS involvement;
chronic PEO with CNS involvement, including pigmentary retinopathy
and hearing loss (chronic PEO/CN); Kearns-Sayre syndrome, as
defined by the triad PEO, pigmentary retinopathy and onset before
age 20 years, plus at least one of the following: cerebellar ataxia,
cardiac conduction block and CSF protein 4100 mg/dl; and sensory
ataxia, neuropathy, dysarthria and ophthalmoplegia (SANDO), as
defined by the combination of sensory ataxia, neuropathy, dysarthria
and ophthalmoplegia. For analytical purposes, patients were grouped
into three genotype groups: point mutations of mitochondrial DNA;
single mitochondrial DNA deletions; and nuclear DNA defects, includ-
ing multiple mitochondrial DNA deletions confirmed in muscle without
an identified nuclear gene defect.
Data analysis
First we performed a descriptive analysis of the clinical and genetic
features of all patients included in the study (n = 116). Second, in the
subgroup of patients with neurophysiological evaluation of the low-
er  upper limbs only (n = 77), we performed the following analyses:
(i) univariate and multivariate analyses with nuclear DNA defect versus
mitochondrial DNA defect as a binary or ternary outcome to evaluate
the associations with predictor variables; (ii) decision tree analysis to
investigate individual variables with optimal performance in genotype
classification; and (iii) assessment of the diagnostic efficiency of the
individual predictors.
Categorical variables were presented as number and percentage.
Contingency tables were analysed using the Pearson’s w2 test or the
Fisher’s exact test, phi (j) coefficients, and odds ratios (ORs) with
their corresponding 95% confidence intervals (CIs) where appropriate.
The Shapiro-Wilk test was used for normality testing. Non-parametric
Figure 1 Flow diagram of the study. *Two patients had
symptoms and/or signs suggestive of peripheral neuropathy but
no documented neurophysiological study. **Neurophysiological
studies of the lower  upper limbs.
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data were presented as median and range or interquartile range (IQR)
and compared using the Mann-Whitney U test or the Kruskal–Wallis
test.
Univariate analyses were performed with the Pearson’s 2 test or
the Fisher’s exact test for categorical variables and with binomial
logistic regression for continuous variables. Forced entry logistic re-
gression was used to examine potential confounders and interactions.
Multivariate analyses were conducted using binomial and multinomial
logistic regression with forward stepwise and forced entry proced-
ures, respectively. The selection and number of variables to be
included in the analyses were guided by P-values on univariate test-
ing (50.05) and number of observations per independent variable
(510). The multinomial logistic regression model with the best fit
was selected using the Akaike’s Information Criterion.
Decision tree analysis is a statistical method that can be used to
create a tree-based classification of cases into groups based on a set
of independent variables, with the purpose of identifying a useful
subset of variables that allow distinction between groups. The same
variables entered in the multinomial logistic regression analysis were
used to construct a decision tree based on the exhaustive ‘Chi-squared
automatic interaction detection’ (CHAID) algorithm with the following
adjustments: 510 and 55 cases per parent node and child node,
respectively; automatic maximum tree depth; Pearson’s 2 statistic;
significant level for splitting nodes set at 50.05 with Bonferroni cor-
rection; and 10-fold cross-validation.
The statistical analyses were performed using IBM SPSS Statistics
version 21 (IBM). All tests were two-tailed and P-values 50.05
were considered statistically significant. A Bonferroni correction was
applied by multiplying P-values by the number of comparisons
where appropriate. The efficiency of each predictor for the diagnosis
of a nuclear DNA defect was examined with its sensitivity, specificity,
positive and negative predictive values and likelihood ratios, calculated
with MedCalc version 12 (http://www.medcalc.org).
Results
Sample characteristics
Sixty females and 56 males from 116 apparently unrelated pedi-
grees were included in the study (full genetic and clinical features
in Supplementary Table 1). The median age at disease onset was
21.3 years (n = 111, IQR 13.6–34.7). PEO was the predominant
presenting symptom in 90 patients (78%). Other patients pre-
sented with the following clinical manifestations or a combination
of them: developmental delay, growth retardation, exercise in-
tolerance, limb weakness, abnormal sensation, gait disturbance,
visual loss, hearing loss, parkinsonism, seizures, stroke-like epi-
sodes, diabetes and heart block. The median follow-up time
from disease onset was 22.3 years (n = 111, IQR 11.0–32.9).
All patients had both ptosis and external ophthalmoplegia with
the exception of one patient with severe ophthalmoplegia and no
ptosis, and one patient with severe ptosis and abnormal ocular
movements but no ophthalmoplegia. Phenotype frequencies
were as follows: 58 patients (50%) had chronic PEO; 41 (35%)
had chronic PEO/CN, including one patient with mitochondrial
encephalopathy, lactic acidosis and stoke-like episodes (MELAS)/
chronic PEO and three with maternally inherited diabetes and
deafness/chronic PEO overlap syndromes; 11 (10%) patients
had Kearns-Sayre syndrome; and six (5%) had SANDO. The clin-
ical features for each phenotype are summarized in Supplementary
Table 2.
Ninety patients (78%) had a primary mitochondrial DNA defect.
Of them, 78 (67%) had a single deletion and 12 (10%) had a
transition mutation in MT-TL1, MT-TL2 or MT-ND4. Eighteen
Figure 2 Frequency of clinical features of patients according to the genotype (n = 116). Forward slash indicates ‘and/or’. *Symptoms
and/or signs suggestive of peripheral neuropathy. **Family history of relatives with similar symptoms or phenotype. COX-deficient/
RRF = cytochrome c oxidase-deficient fibres and/or ragged-red fibres in muscle histochemistry.
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patients (16%) had pathogenic variants in either POLG, C10orf2
or RRM2B, and eight (7%) had multiple mitochondrial DNA de-
letions detected in muscle without an identified nuclear gene
defect. Of these eight patients, seven had undergone sequence
analysis of the coding region of POLG and a targeted mutation
screen of C10orf2, and five had also undergone analysis of the
coding region of RRM2B and SLC25A4. The clinical features for
each genotype are shown in Fig. 2 and Supplementary Table 2.
There was a significant difference in the overall distribution
of phenotypes between genotypes (P5 0.001) (Fig. 3 and
Supplementary Table 3). Subgroups analysis disclosed direct asso-
ciations (positive j coefficient) between chronic PEO/CN and
point mutations of mitochondrial DNA (P = 0.004), between
SANDO and nuclear DNA defects (P5 0.001), and between
Kearns-Sayre syndrome and single mitochondrial DNA deletions
(P = 0.015). Only the first two associations, however, retained
statistical significance after Bonferroni adjustment (P = 0.048,
P5 0.001 and P = 0.132, respectively).
From the total of 116 patients included in the study, 77 (66%)
had neurophysiological studies performed in the lower  upper
limbs. The median age at examination was 46.9 years (IQR
30.3–54.4). Except for gender distribution, frequency of proximal
muscle weakness and frequency of peripheral neuropathy symp-
toms/signs, there were no demographic and clinical differences
between this group of 77 patients and the remaining 39
(Supplementary Table 4). Of this latter group, one had signs
and symptoms suggestive of sensory neuropathy (chronic PEO/
CN phenotype; C10orf2 mutation), and one had reduced vibration
sense at the malleolus and absent right ankle jerk at age 73 years
(chronic PEO phenotype; single mitochondrial DNA deletion).
Of the 77 patients with neurophysiological studies performed in
the lower  upper limbs, 16 (21%) had a large-fibre peripheral
neuropathy confirmed by nerve conduction studies: 13 patients
with and three patients without sensory or motor symptoms
and/or signs. Five patients had symptoms and/or signs but no
neuropathy on nerve conduction studies: two asymptomatic with
abnormal sensory examination; two with symptoms but normal
examination; and one with sensory symptoms and reduced ankle
jerks concomitant to gold salt therapy for rheumatoid arthritis. In
this latter case, nerve conduction studies showed reduced sural
sensory nerve action potential amplitudes (4 and 3 mV) that re-
mained stable or improved over time (5 and 8mV). One patient
had a severe L4/5 radiculopathy with asymmetric sensory nerve
action potential amplitudes in the lower limbs. The remaining 55
patients had no symptoms and no neurophysiological evidence of
peripheral neuropathy (sural sensory nerve action potential ampli-
tude: median 17 mV; range 7–50 mV).
Peripheral neuropathy
The genetic and clinical features of the 16 patients with peripheral
neuropathy are summarized in Table 1 (neurophysiological data in
Supplementary Table 5). In this group, the median age at disease
onset was 31.9 years (IQR 24.1–49.7). One patient (6%) had a
single mitochondrial DNA deletion, four (25%) had the
m.3243A4G mutation, nine (56%) had POLG mutations, one
(6%) had multiple mitochondrial DNA deletions in muscle with
negative sequence analysis of POLG and C10orf2, and one
(6%) had multiple mitochondrial DNA deletions in muscle with
negative sequence analysis of POLG, C10orf2, RRM2B and
SLC25A4. Except for diabetes in three patients with
m.3243A4G, none of them had endocrine–metabolic disorders
that could account for the peripheral neuropathy.
In all the patients with a primary mitochondrial DNA defect, the
peripheral neuropathy was asymptomatic. The neurophysiological
pattern was consistent with a length-dependent, predominantly
sensory or sensorimotor neuropathy. In two patients, the data
Figure 3 Phenotype-genotype distribution of patients (n = 116):
proportion of patients for each phenotype with single mito-
chondrial DNA deletions, point mutations of mitochondrial DNA
(MT-TL1, MT-TL2 and MT-ND4 genes), mutations in nuclear
genes (POLG, C10orf2 and RRM2B) or multiple mitochondrial
DNA deletions in muscle without an identified nuclear gene
defect (*). CPEO = chronic PEO. CPEO/CN = chronic PEO with
CNS involvement. KSS = Kearns-Sayre syndrome.
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available was insufficient to characterize the neuropathy further. In
three patients with m.3243A4G and diabetes, the peripheral
neuropathy was axonal with mild slowing of sensory and motor
conduction velocities. Only one patient with absent sensory and
motor responses in the lower limbs had distal neurogenic changes
on EMG.
The presenting manifestation in patients with a nuclear DNA
defect and peripheral neuropathy was a variable combination of
upper or lower limb sensory symptoms and ataxia with or without
other features (PEO, dysarthria, parkinsonism or myoclonic jerks)
in seven patients; PEO in two patients; stroke and epilepsy in one
patient; and epilepsy and myoclonic jerks in one patient. All of
them had abnormal sensory examination and abnormal tendon
reflexes, and three had distal limb weakness.
The neurophysiological patterns in patients with a POLG muta-
tion were as follows: unobtainable sensory responses and normal
motor studies in three patients; non-length dependent, predomin-
antly sensory, axonal neuropathy with distal active and chronic
neurogenic changes on EMG in two patients; and length-depend-
ent, sensory or sensorimotor axonal neuropathy in three patients,
one of them with mild slowing of sensory and motor conduction
velocities. In one patient, data was incomplete but suggestive of a
predominantly sensory axonal neuropathy. The neurophysiological
pattern in patients with multiple mitochondrial DNA deletions
without an identified nuclear gene defect was consistent with a
non-length dependent, predominantly sensory neuropathy with
distal and proximal chronic neurogenic changes on EMG in one
case, and with a length-dependent, predominantly sensory axonal
neuropathy in another case.
Predictors for nuclear DNA defect
The demographic and clinical characteristics of patients with
neurophysiological studies of the lower  upper limbs classified
by genotype are summarized in Supplementary Tables 6 and 7.
Age at disease onset, gender, family history, PEO/ptosis as the
presenting feature, pigmentary retinopathy, peripheral neuropathy
and parkinsonism/dystonia were significantly different in patients
with a nuclear DNA defect as compared to patients with a primary
mitochondrial DNA defect (point mutation or single deletion) eval-
uated as a group. The presence of ataxia was also associated with
a nuclear DNA defect; after adjusting for the presence of periph-
eral neuropathy, however, this parameter did not retain statistical
significance and therefore was not entered in the multivariate ana-
lysis. Differences were found in the distribution of the following
characteristics between the three individual genotypes: age at dis-
ease onset, gender, family history, PEO/ptosis as the presenting
feature, pigmentary retinopathy, hearing loss, ataxia, seizures/epi-
lepsy, stroke/stroke-like episodes, parkinsonism/dystonia, periph-
eral neuropathy and diabetes.
Logistic regression analyses were performed to determine the
independent factors associated with a nuclear DNA defect as a
binary or ternary outcome (Tables 2 and 3). Binomial logistic re-
gression identified peripheral neuropathy as the only independent
predictor associated with nuclear DNA defect (P = 0.002; OR 8.43,
95% CI 2.24–31.76). Multinomial logistic regression was con-
ducted using nuclear DNA defect as the reference group. Three
variables were identified as significant predictors of the genotype:
peripheral neuropathy, family history and hearing loss. The ab-
sence of peripheral neuropathy and a negative family history
were significant in differentiating patients with a single mitochon-
drial DNA deletion from those with a nuclear DNA defect
(P5 0.001; OR 55.90, 95% CI 5.96–524.12; and P = 0.005; OR
9.35, 95% 1.95–44.82, respectively). The absence of hearing loss
was significant in differentiating patients with a nuclear DNA
defect from those with a point mutation of mitochondrial DNA
(P = 0.007; OR 0.04, 95% CI 0.004–0.43). Diagnostic properties
of the three predictor variables are summarized in Table 4.
Decision tree
A decision tree was constructed using the following variables:
gender, family history, PEO/ptosis as the presenting feature, pig-
mentary retinopathy, hearing loss and peripheral neuropathy
(Fig. 4). Age at disease onset was converted into the dichotomous
variable ‘onset before age 30 years’ and also entered in the ana-
lysis. Based on 2 statistics, the variables with highest discrimin-
atory power were peripheral neuropathy [2(2) = 25.7,
P50.001], which split the parent node into two child nodes
(nodes 1 and 2), followed by family history [2(2) = 14.5,
P = 0.001] and hearing loss [2(2) = 9.0, P = 0.011]), which split
nodes 1 and 2 into four terminal nodes (3 to 6).
The highest probability (86%) of having a single mitochondrial
DNA deletion was observed among patients with no peripheral
neuropathy and a negative family history (node 3); the highest
probability (90%) of having a nuclear DNA defect was observed
among patients with peripheral neuropathy and no hearing loss
(node 5); and the highest probability (67%) of having a point
mutation of mitochondrial DNA was detected among patients
with peripheral neuropathy and hearing loss (node 6). The overall
classification accuracy of the decision tree was 78% (89%, 67%
and 44% for single mitochondrial DNA deletion, point mutation of
mitochondrial DNA and nuclear DNA defect, respectively).
Discussion
The main findings of this study are: (i) the most common genetic
defect associated with PEO in patients with mitochondrial disease
is a single mitochondrial DNA deletion, in line with previous stu-
dies (Zeviani et al., 1988; Holt et al., 1989; Moraes et al., 1989;
Rodrı´guez-Herna´ndez et al., 2000; Jime´nez Caballero et al., 2007;
Martikainen et al., 2012); (ii) peripheral neuropathy is a rare clin-
ical feature in patients with a single mitochondrial DNA deletion;
and (iii) in the present patient sample, among several individual
clinical features, peripheral neuropathy was the most important in
predicting the genetic defect in patients with PEO caused by mito-
chondrial disease, followed by family history and hearing loss.
Genotypes and clinical features
In this sample of 116 probands with genetically-defined mitochon-
drial disease and PEO, 67% of cases were due to a single mito-
chondrial DNA deletion. Fifty-seven per cent of these patients had
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a chronic PEO phenotype with bulbar or limb weakness. The re-
maining 43% had chronic PEO/CN or Kearns-Sayre syndrome.
The median age of onset was 7.3 years lower in patients with
chronic PEO/CN than in patients with chronic PEO, consistent
with previous studies evaluating the natural history of patients
with a single mitochondrial DNA deletion (Aure et al., 2007). As
expected from the phenotype classification, patients with Kearns-
Sayre syndrome had also a younger age at disease onset. Except
for pigmentary retinopathy and hearing loss, and ataxia and pyr-
amidal features in patients with Kearns-Sayre syndrome, the fre-
quency of other CNS symptoms such as epilepsy, myoclonus or
extrapyramidal features was low. Four patients with a single mito-
chondrial DNA deletion were said to have a family history of simi-
lar symptoms or phenotype but this was not confirmed genetically.
Ten per cent of patients had a point mutation of mitochondrial
DNA. Three had a chronic PEO phenotype, two of them with
exercise intolerance and proximal muscle weakness; these have
been described in detail elsewhere (Sweeney et al., 1993; Pulkes
et al., 2003). Nine patients had the m.3243A4G mutation, all of
them with a chronic PEO/CN phenotype. The most prevalent
extramuscular manifestations in this group were hearing loss and
diabetes. These were also the commonest features (51% and
42%, respectively) in a large cohort of 129 individuals with the
m.3243A4G mutation (Nesbitt et al., 2013). In only three cases,
symptoms conformed to well-recognized clinical syndromes
(maternally inherited diabetes and deafness and MELAS) in com-
bination with PEO.
Sixteen per cent of patients had a nuclear DNA defect. Three
nuclear genes were associated with PEO in the present study:
POLG, C10orf2 and RRM2B. Mutations in these genes were re-
sponsible for 11%, 3% and 1% of all cases, respectively. In line
with previous studies, p.A467T followed by p.W748S were the
most common variants identified in patients with two POLG mu-
tations (Tang et al., 2011; Neeve et al., 2012). Six patients had
SANDO: five of them were compound heterozygous for patho-
genic POLG mutations and one was heterozygous for a patho-
genic POLG mutation. One additional patient had a clinical picture
suggestive of SANDO; in this case, however, the ataxia might
Table 3 Multinomial logistic regression analysis of patients classified by genotype (n = 77)
Nuclear DNA defect versus single
mitochondrial DNA deletion
Nuclear DNA defect versus point
mutation of mitochondrial DNA
OR (95% CI) B (SE) P OR (95% CI) B (SE) P
Peripheral neuropathy
Present (ref.) 1 1
Absent 55.90 (5.96–524.12) 4.02 (1.14) 0.000 3.13 (0.34–28.42) 1.14 (1.13) 0.312
Family history
Positive (ref.) 1 1
Absent 9.35 (1.95–44.82) 2.24 (0.80) 0.005 0.48 (0.06–3.92) 0.73 (1.07) 0.494
Hearing loss
Present (ref.) 1 1
Absent 0.42 (0.04–3.98) 0.88 (1.15) 0.447 0.04 (0.004–0.43) 3.15 (1.17) 0.007
Reference category for equations = nuclear DNA defect; Model 2 (6) = 54.6, P5 0.001; Goodness-of-fit (Pearson) P = 0.881; R2 (Nagelkerke) = 0.607; overall accuracy of
classification = 80.5%. SE = standard error.
Table 4 Test characteristics of peripheral neuropathy, family history and hearing loss in the diagnosis of patients with a
nuclear DNA defect (n = 77)
Prevalence Sensitivity Specificity PPV NPV + LR LR
Peripheral neuropathy 21% 52% 91% 69% 83% 5.87 0.52
Positive family history 26% 43% 80% 45% 79% 2.18 0.71
Hearing loss 21% 14% 77% 19% 70% 0.62 1.12
PPV = positive predictive value; NNV = negative predictive value; + LR = positive likelihood ratio; LR = negative likelihood ratio.
Table 2 Binomial logistic regression analysis of patients classified by genotype (nuclear DNA defect versus mitochondrial
DNA defect; n = 77)
B (SE) P OR 95% CI
Peripheral neuropathy (present) 2.13 (0.68) 0.002 8.43 2.24–31.76
Gender (male) 1.43 (0.73) 0.051 4.16 0.99–17.41
Model 2 (2) = 21.0, P50.001; Hosmer and Lemeshow P = 0.931; R2 (Nagelkerke) = 0.356; overall accuracy of classification = 81.3%. SE = standard error.
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have been secondary to a cerebellar infarct and was classified as
chronic PEO/CN. One patient with the p.T423S variant in C10orf2
had a phenotype suggestive of SANDO except for the absence of
ophthalmoplegia. Other patients with C10orf2 had chronic PEO
with no CNS features.
Seven per cent of patients had multiple mitochondrial DNA dele-
tions in muscle without an identified nuclear gene defect and had
chronic PEO with or without CNS involvement. Except for three cases
of isolated chronic PEO, no specific combination of symptoms was
observed that was common to any two or more of these patients.
Figure 4 Ten-fold cross-validated, exhaustive Chi-squared automatic interaction decision tree for classification of genotypes according to
individual clinical features (n = 77). Percentages and bars for each genotype (category) indicate the relative proportion of patients within
each node. Total percentages represent the proportion of patients in each node relative to the initial sample. Adj. P-value = adjusted P-
value; df = degrees of freedom; nDNA = nuclear DNA defect; PM mtDNA = point mutation of mitochondrial DNA; SD mtDNA = single
mitochondrial DNA deletion.
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Peripheral neuropathy
In this study, peripheral neuropathy was an extremely rare feature
in patients with a single mitochondrial DNA deletion: only 1 of 47
patients (2%) had a probable subclinical sensory neuropathy. In
contrast, the prevalence of peripheral neuropathy confirmed by
nerve conduction studies in patients with point mutations of mito-
chondrial DNA and nuclear DNA defects was significantly higher
(44% and 52%, respectively).
The mechanisms of single deletion formation remain incom-
pletely understood, although the process probably takes place
during oogenesis or early embryogenesis (Pitceathly et al.,
2012). Deleted genomes could subsequently populate different
tissues and expand clonally during development. Disparities in
tissue distribution and mutation load have been proposed to
account for at least part of the phenotypic variability
observed among patients with chronic PEO, chronic PEO/CN
and Kearns-Sayre syndrome (Moraes et al., 1989; Ponzetto
et al., 1990; Aure et al., 2007). Deleted mitochondrial DNA spe-
cies have indeed been demonstrated in most tissues in patients
with Kearns-Sayre syndrome, in keeping with the multisystemic
nature of the disease (Ponzetto et al., 1990; Kageyama et al.,
1991; Brockington et al., 1995; Boles et al., 1998).
Theoretically, the observed low frequency of neuropathy in pa-
tients with a single mitochondrial DNA deletion could be explained
by differences in mutation load or tissue susceptibility. To our
knowledge, however, the presence and load of single mitochon-
drial DNA deletions has not been studied in peripheral somatic
nerves in patients with mitochondrial disease.
The prevalence of neuropathy in patients with m.3243A4G has
been reported to range between 5% and 77% (Chinnery et al.,
1997; Ka¨rppa¨ et al., 2003; Kaufmann et al., 2006; Liu et al.,
2012). In a previous study, neurophysiological examination of
seven patients with m.3243A4G disclosed a peripheral neur-
opathy with mixed axonal and demyelinating features in six
cases and uniform demyelinating features in one case. Four of
these patients had diabetes (Ka¨rppa¨ et al., 2003). In another
study, from a total of 23 patients with m.3243A4G and periph-
eral neuropathy, the neurophysiological pattern was axonal, mixed
or demyelinating in 52%, 30% and 17% of cases, respectively.
Nine of these patients had abnormal fasting glucose levels
(Kaufmann et al., 2006). We identified a total of nine patients
with PEO and m.3243A4G, three of them with peripheral neur-
opathy and diabetes. Nerve conduction studies were consistent
with an axonal neuropathy with mild slowing of conduction velo-
cities, in a pattern reminiscent of that seen in individuals with
distal symmetrical diabetic polyneuropathy without mitochondrial
disease (Partanen et al., 1995; Herrmann et al., 2002). Although
the presence of the m.3243A4G mutation has been demon-
strated in peripheral nerves (Love et al., 1993), whether the neur-
opathy in these patients is due to mitochondrial dysfunction,
diabetes or both is unclear.
A sensory ataxic neuropathy or neuronopathy is a frequent fea-
ture in patients with recessive POLG mutations, particularly in
adults, and often presents in association with dysarthria and
PEO (Fadic et al., 1997; Van Goethem et al., 2003; Tang et al.,
2011; Lax et al., 2012). Nerve conduction studies usually show
absent sensory responses in the lower limbs and absent or reduced
sensory nerve action potential amplitudes in the upper limbs, and
motor axonal involvement is also described in some cases (Fadic
et al., 1997; Lax et al., 2012). The existence of multiple deletions
and depletion of mitochondrial DNA as well as mitochondrial re-
spiratory-chain defects have been confirmed in dorsal root ganglia
neurons from one patient with recessive POLG mutations, estab-
lishing a direct aetiological link between mitochondrial dysfunction
and the neuronopathy (Lax et al., 2012). In the present study,
69% of patients with PEO due to POLG mutations had peripheral
neuropathy, a higher figure than previously reported (Horvath
et al., 2006), and POLG mutations were the commonest cause
of peripheral neuropathy. Most patients presented with a predom-
inantly sensory neuropathy and five of them had clinical and
neurophysiological features consistent with a sensory neuronopa-
thy: sensory deficits with or without ataxia, plus a non-length
dependent sensory axonal neuropathy or unobtainable sensory
responses.
Peripheral neuropathy has been reported in only a small number
of patients with PEO and C10orf2 or RRM2B mutations (Fratter
et al., 2010; Pitceathly et al., 2012). We did not observe symp-
toms suggestive of neuropathy in patients with mutations in these
genes except in one patient that developed a possible peripheral
neuropathy related to gold salt therapy in the past. In this case, a
follow-up study after a 7-year interval did not reveal progression
of the neurophysiological abnormalities.
Predictive factors
Among the individual clinical features with unequal distribution
between genotype groups, including age of onset, gender,
family history, PEO/ptosis as the presenting feature, pigmentary
retinopathy and hearing loss, peripheral neuropathy was the one
with highest ability to predict and discriminate between geno-
types, particularly between nuclear DNA defect and single mito-
chondrial DNA deletion, as shown by both logistic regression and
decision tree analysis. The odds of a patient with PEO and per-
ipheral neuropathy having a nuclear DNA defect was 8.43 (95%
CI 2.24–31.76) times higher than those of a patient with PEO but
no peripheral neuropathy. Of the clinical features which predicted
the genotype, peripheral neuropathy had the highest specificity
(90%), negative predictive value (83%) and positive likelihood
ratio (5.87) for the diagnosis of a nuclear DNA defect. The rela-
tively low frequency of peripheral neuropathy among patients
with PEO (21%), however, explains the low sensitivity (52%).
Both multinomial regression and decision tree analysis identified
two other variables with predictive and classification ability: family
history and hearing loss. Family history is clearly a useful feature in
the differential diagnosis of mitochondrial disease. However, a
negative family history in first-degree relatives could be explained
by either a sporadic single mitochondrial DNA deletion or an auto-
somal recessive nuclear DNA defect. In the present sample, 50%
of patients with a nuclear DNA defect did not have a family his-
tory of similar symptoms or phenotype. Hearing loss is a frequent
feature in patients with m.3243A4G. In this study, in contrast, it
was observed in only a small proportion of patients with a single
mitochondrial DNA deletion or a nuclear DNA defect.
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We believe that these findings have clinical implications. First,
patients presenting with PEO and suspected mitochondrial disease
should be carefully examined to exclude or confirm the presence
of peripheral neuropathy, since this may be helpful in the selection
of genetic tests. Second, the finding of peripheral neuropathy in a
patient with PEO and a single mitochondrial DNA deletion should
prompt the investigation to exclude alternative aetiologies. Third,
certain combinations of clinical features are highly suggestive of
the underlying genetic defect and may guide the diagnostic inves-
tigations. For instance, 90% of patients with PEO, peripheral
neuropathy and no hearing loss, and 67% of patients with PEO,
peripheral neuropathy and hearing loss, had a nuclear DNA defect
or a point mutation of mitochondrial DNA (m.3243A4G),
respectively. Genetic testing for these defects can be initially per-
formed in DNA extracted from blood and, if confirmed, this may
avoid the need for invasive procedures (Rahman and Hanna,
2009).
Limitations
This study has several limitations. First, the design of the study did
not allow a prospective standardized evaluation of patients. In this
regard, the diagnosis of peripheral neuropathy was made on the
basis of retrospectively collected clinical information and neuro-
physiological studies that were not always performed using the
same protocol. All patients, however, had been assessed by
experienced clinicians at the National Hospital for Neurology and
Neurosurgery and a detailed and systematic collection of clinical
information was carried out in all cases to minimize loss of data.
Second, this was a single-centre study and the sample might not
be representative of the whole patient population. However, the
frequency distribution of genotypes among patients with PEO is
similar to that observed in other case series (Holt et al., 1989;
Jackson et al., 1995; Rodrı´guez-Herna´ndez et al., 2000), studies
based on single-centre experience (Jime´nez Caballero et al.,
2007), and population-based studies (Martikainen et al., 2012).
In addition, to minimize selection biases, all patients with PEO
and mitochondrial disease that were assessed at our centre and
with clinical information available were included in the study.
Third, although this study comprised a large number of patients
with mitochondrial disease, the sample size did not allow us to
examine the predictive value of those clinical manifestations that
were observed in only a minority of cases (e.g. stroke-like epi-
sodes, epilepsy, parkinsonism) or the predictive value of specific
peripheral neuropathy subtypes (e.g. neuronopathy versus axonal
with slowing of conduction velocity). Finally, this study only
included patients with PEO due to mitochondrial disease.
Therefore, results cannot be generalized to an unselected popula-
tion of patients with ptosis or ophthalmoplegia but to patients
with suspected mitochondrial disease in whom other disorders
have been excluded on clinical grounds.
Conclusion
This study highlights the phenotypic and genotypic heterogeneity
of mitochondrial diseases but also that the analysis of a large case
series may help establish consistent phenotype–genotype correl-
ations. The results indicate that peripheral neuropathy is a rare
finding in patients with single mitochondrial DNA deletions and
that the presence of peripheral neuropathy is highly predictive of
an underlying nuclear DNA defect, particularly POLG mutations.
This observation will facilitate future development of more effi-
cient diagnostic algorithms to aid clinicians when selecting and
interpreting molecular genetic investigations.
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